FDA
-
-
-
-
-
-
-
Syndax presents Revuforj clinical data across acute leukemia subtypes
-
-
-
-
-
-
-
SYNDAX highlights revumenib post-transplant data at ASCO 2026
-
-
-
-
-
-
-
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
-
-
-
-
-
-
-
Syndax Announces Participation in March Investor Conferences
-
-
-
-
-
-
-
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
-
328,164 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

